J Cancer Metastasis TreatJournal of Cancer Metastasis and Treatment2454-2857OAE Publishing Inc.10.20517/2394-4722.2019.43ReviewUnlikely role of glycolytic enzyme α-enolase in cancer metastasis and its potential as a prognostic biomarkerSchofieldLachlan12LinczLisa F.123kathryn.skelding@newcastle.edu.auSkeldingKathryn A.121Faculty of Health and Medicine, Priority Research Centre for Cancer Research, Innovation and Translation, School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales 2308, Australia.2Hunter Cancer Research Alliance and Cancer Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales 2305, Australia.3Hunter Haematology Research Group, Calvary Mater Newcastle Hospital, Waratah, New South Wales 2298, Australia.Correspondence Address: Dr. Kathryn A. Skelding, School of Biomedical Sciences and Pharmacy, University of Newcastle, University Drive, Callaghan, New South Wales 2308, Australia. E-mail: kathryn.skelding@newcastle.edu.au
Received: 5 Dec 2019 | First Decision: 4 Mar 2020 | Revised: 5 Mar 2020 | Accepted: 24 Mar 2020 | Published: 17 Apr 2020
Science Editor: Stephen J. Ralph | Copy Editor: Jing-Wen Zhang | Production Editor: Jing Yu
Reliance on glycolysis for energy production is considered a hallmark of cancer and the glycolytic enzyme α-enolase is overexpressed in a range of cancer types. However, recent studies have revealed that α-enolase is involved in a variety of unrelated physiological processes and can be found in multiple unexpected cellular locations. This review focuses on the unlikely role of α-enolase as an extracellular plasminogen-binding receptor localised to the plasma membrane. Conversion of plasminogen to plasmin on the surface of cancer cells enhances their ability to invade through stroma by activating collagenases and degrading fibrin as well as extracellular matrix proteins. Increased expression of α-enolase is associated with increased migration and invasion of cancer cells, and decreased metastasis-free survival in patients with several cancer types, including non-small cell lung, pancreatic, breast and colorectal cancers. Due to its overexpression in a range of cancer types and multi-functional roles in key areas of tumour metabolism and metastasis, α-enolase may be useful as a universal cancer prognostic biomarker or therapeutic target.
All cancer cells have a high energy demand due to their increased rate of proliferation[1]. Increased glycolysis is considered a hallmark of cancer[2] and investigating glycolytic enzymes may yield new therapeutic approaches for cancer treatment. Enolases are key glycolytic enzymes[3], and increased expression of one isoform, α-enolase, has been identified in several cancer types[4-22]. This review provides an overview of the expression of α-enolase and key functions it controls in cancer cells, with a focus on the potential role of α-enolase as a cancer prognostic biomarker or therapeutic target.
Enolase is a glycolytic enzyme that has three isoforms
Enolases (EC 4.2.1.11) are metalloenzymes that catalyse the dehydration of 2-phospho-D-glycerate to phosphoenolpyruvate in the glycolysis pathway [Figure 1], and catalyse the hydration of phosphoenolpyruvate to 2-phopho-D-glycerate in the reverse anabolic pathway during gluconeogenesis[3]. In mammals, the three genes ENO1, ENO2, ENO3 encode three isoforms, with expression being regulated in a tissue-specific manner. Alpha-enolase (ENO1) is ubiquitously expressed, whereas γ-enolase (ENO2) is primarily expressed in neurons and neuroendocrine tissues, and β-enolase (ENO3) in muscle tissues[23]. Active enolase consists of a dimer in which two subunits face each other in an antiparallel formation[24], and requires two non-covalently bound magnesium ions as cofactors for enzyme activity[25].
The glycolysis pathway. Enolases catalyse the dehydration of 2-phospho-D-glycerate (2-P-glycerate) to phosphoenolpyruvate (P-enolpyruvate) in the glycolysis pathway
Alpha-enolase is a multi-functional protein
Although many glycolytic enzymes are considered to be housekeeping proteins, α-enolase expression can vary dramatically depending on the stress, metabolic, or pathological state of the cell. A retrospective proteomic meta-analysis identified that α-enolase was the most differentially expressed protein in humans and rodents irrespective of tissue type and pathological condition[26]. Disrupted expression and/or activity of α-enolase has been reported in several pathologies with distinct aetiologies, including Alzheimer’s disease, systemic sclerosis, rheumatoid arthritis, bacterial infections and hepatic fibrosis[27-38].
Apart from its role in the glycolytic pathway, recent studies have revealed that α-enolase is a multi-functional protein that controls a variety of cellular processes, including proliferation, survival, migration and invasion. Additionally, using an alternative transcription start codon, the ENO1 gene can produce a 37 kDa protein, c-myc promoter-binding protein (MBP-1). MBP-1 localises to the nucleus, where it acts as a transcription repressor by binding to the c-myc P2 promoter[39], helping regulate and maintain the function of the glycolysis pathway.
Alpha-enolase expression is altered in tumours and varies with cancer type
The overexpression of α-enolase is associated with tumour development via a process known as aerobic glycolysis or the Warburg effect. The Warburg effect has been hypothesised to be an adaptation mechanism in cancer cells to support the biosynthetic requirements of rapid proliferation. Alpha-enolase expression has been shown to be altered at the mRNA and/or protein level in a range of tumours [Table 1], and generally upregulated in most, including acute myeloid leukaemia (AML), glioma, melanoma, lymphoma, and colorectal, endometrial, gastric, head and neck, liver, ovarian and pancreatic cancer[4-22].
The expression of α-enolase is altered in cancer
Cancer
Sample type
Detection method
Alteration (frequency of alteration)
Ref.
AML
Peripheral blood and bone marrow from AML patients (n = 41) and healthy patients (n = 20)
Microarray
Increased
[4]
Breast cancer
Breast cancer tissue with adjacent matched normal tissue (n = 24)
Western blot
Increased (100%)
[9]
Breast cancer and normal tissue (n = 244)
Quantitative real-time PCR
Decreased
[10]
Cervical cancer
Squamous cell carcinoma (n = 33) and normal cervical tissue (n = 17)
2D-DIGE and MALDI-TOF mass spectrometry
Increased
[40]
Colorectal cancer
SW620 cell line (lymph node metastasis) compared to SW480 (primary lesion)
2D-DIGE
Increased
[41]
Colorectal cancer (n = 48) and adjacent matched normal tissue (n = 16)
IHC and PCR
Increased (56%)
[11]
Endometrial carcinoma
Endometrial cancer (n = 100), endometrial atypical hyperplasia (n = 22) and normal endometrium tissues (n = 20)
IHC
Increased in endometrial cancer (52%) and atypical hyperplasia (31.8%) compared to normal
[12]
Gastric cancer
Gastric cancer and adjacent normal tissue (n = 94)
IHC
Increased
[13]
Primary gastric cancer tissue (n = 107)
IHC
Increased (48%)
[14]
Glioma
Primary glioblastoma tissue (n = 24)
Quantitative real-time PCR
Increased (68%)
[5]
Glioma (n = 136) and normal brain (n = 15) tissue
Quantitative real-time PCR and IHC
Increased (69%)
[6]
Head and neck cancer
Head and neck cancer and adjacent normal tissue (n = 44)
Real-time PCR
Increased (50%)
[15]
HCC
HCC (n = 374 and n = 1309), adjacent matched tissue (n = 50), and normal tissue (n = 1442) from TCGA and GEO data source; tissue microarray (93 HCC and 87 normal liver tissues)
Microarray and IHC
Increased
[16]
Lymphoma
Pretherapeutic tumour biopsies from peripheral T-cell lymphoma not otherwise classified (n = 87)
IHC
Increased
[8]
Melanoma
A375, MeWo, MEL-HO, Colo-800, Colo-853 melanoma cell lines and a normal melanocyte cell line
2D-DIGE and nano-HPLC-chip ion trap mass spectrometry
Increased
[7]
NSLC
Primary NSCLC tissue and matched normal lung (n = 26) from RNA and primary NSCLC tissue (n = 55) and normal lung tissue (n = 17)
Real-time PCR and IHC
Increased
[17]
Primary NSCLC and adjacent matched normal tissue (n = 46)
Western blotting
Decreased (26%)
[42]
Primary NSCLS tissue (n = 36)
PCR
Increased (16%)
[18]
Ovarian cancer
Ovarian cancer (n = 4) and ovarian tissue from endometriosis (n = 1)
2D-DIGE and LC-MS/MS
Increased
[19]
Pancreatic cancer
Pancreatic cancer and adjacent normal tissue (n = 31)
IHC
Increased
[20]
Pancreatic cancer (n = 100) and adjacent normal tissue (n = 80)
IHC
Increased (48%)
[21]
Primary pancreatic and adjacent normal tissue (n = 3)
Western blot
Increased
[22]
Prostate cancer
Exosomes from prostate cancer cell lines
Western blot and mass spectrometry
Decreased
[43]
2D-DIGE: two-dimensional differential in gel electrophoresis; HCC: hepatocellular carcinoma; HPLC: high performance liquid chromatography; IHC: immunohistochemistry; LC-MS/MS: liquid chromatography tandem mass spectrometry; MALDI-TOF: matrix assisted laser desorption/ionization time of flight; NSCLC: non-small cell lung cancer; PCR: polymerase chain reaction; AML: acute myeloid leukaemia; TCGA: the cancer genome atlas; GEO: gene expression omnibus
Alpha-enolase can shuttle between cellular compartments
Alpha-enolase can be localised to the cytoplasm and plasma membrane, as well as secreted in exosomes, and its location varies with cancer type. For example, in pancreatic, breast and lung tumours, α-enolase is localised to the plasma membrane[22,44,45], whereas in melanoma, mesothelioma, non-small cell lung, colorectal and prostate cancer α-enolase is also secreted and found in exosomes[43,46-49]. Alpha-enolase can shuttle between compartments, performing different functions when in different subcellular locations, such as surface membrane plasminogen binding, controlling the overall metabolic state of the cell, stress-related or acting as a heat-shock protein, RNA transport, mitochondrial membrane stability, and cell cycle control[50-55].
Increased alpha-enolase expression enhances cell proliferation in a variety of cancers
In most solid tumours, the Warburg effect causes an increase in total glycolysis under both hypoxic and normoxic conditions [Figure 2]. Enhanced cell proliferation leads to increased anabolic needs, and cancer cells remodel metabolic processes by diverting nutrients to anabolic pathways to satisfy increased cellular energy demands[56]. Therefore, the Warburg effect may provide cancer cells with an advantage when competing with non-cancerous tissues for nutrients. This suggests that increased α-enolase expression will contribute to enhanced proliferation commonly observed in cancer cells.
The Warburg Effect in cancer cells. In the presence of oxygen, differentiated tissues first metabolise glucose to pyruvate via glycolysis and then oxidise the majority of the pyruvate to carbon dioxide via oxidative phosphorylation. In situations where oxygen is low, cells redirect pyruvate generated by glycolysis away from oxidative phosphorylation by generating lactate via anaerobic glycolysis. By contrast, cancer cells convert most glucose to pyruvate regardless of whether oxygen is present. This allows cancer cells to meet the increased cellular energy demands
Indeed, upregulated α-enolase expression has been shown to regulate cell proliferation in various solid tumours in vitro[11,13,57-61], and to increase tumour growth in a HCT116 colorectal cancer xenograft model in vivo[11][Table 2]. Conversely, silencing of α-enolase in glioma, pancreatic, lung, endometrial, colorectal and breast cancer cells was found to induce cell cycle arrest and senescence, and also to reduce tumour volume in CFPAC-1 pancreatic, MDA-MB-231 breast and U-87MG glioma xenograft models in vivo[6,11,12,62,63]. Furthermore, α-enolase is also implicated in the control of apoptosis and sensitivity to chemotherapeutic agents, as silencing of ENO1 in cancer cells induced apoptosis and increased sensitivity to cisplatin and 5-fluorouracil in vitro[13,62,64]. Unexpectedly, cells respond to α-enolase silencing by inducing catabolic adaptations that lead to restoration of pyruvate, acetyl-CoA bulk and oxidative phosphorylation, and exhibit an increased expression of proteins involved in both oxidative stress- and sirtuin-induced autophagy[62]. Taken together, these studies demonstrate that α-enolase is an important regulator of tumour cell metabolism, proliferation and survival, which by definition make it a perfect target for anticancer therapy.
Alpha-enolase controls cancer cell proliferation and survival
Cancer
Experimental model
Effect of modulation of ENO1 expression
Ref.
Bladder cancer
Overexpression and knockdown in T253 and 5637 cells
Knockdown decreased cell proliferation and colony formation. Overexpression increased cell proliferation and colony formation
[59]
Breast cancer
Downregulation in MDA-MB-231 cells
Downregulation decreased cell proliferation and survival in vitro and reduced tumour growth in vivo
[62]
Colorectal cancer
Overexpression and knockdown in HCT116 cells
Overexpression promoted cell proliferation and tumour growth in vivo; Decreased expression decreased cell proliferation and tumour growth in vivo
[11]
Endometrial carcinoma
Knockdown in HEC-1B and Ishikawa
Decreased expression reduced cell proliferation in vitro and tumourigenesis in vivo
[12]
Gastric cancer
Knockdown in MGC-803 and MKN45 cells
Knockdown led to cell cycle arrest at the G1 phase and promoted apoptosis, and repressed the rate of cell proliferation and colony formation
[13]
Knockdown in MKN45 cells
Knockdown decreased cell proliferation, induced apoptosis and increased sensitivity to chemotherapeutics
[64]
Knockdown in AGS cells and overexpression in SGC7901 cells
Knockdown decreased proliferation and colony formation, whereas overexpression increased cell proliferation and colony formation
[60]
Overexpression in AGS cells
Overexpression increased cell proliferation and colony formation
[61]
Glioma
Knockdown in U-87MG cells
Knockdown suppressed cell proliferation and colony formation in vitro and tumour growth in vivo
[6]
HCC
Knockdown in HCC cells
Knockdown inhibited cell growth
[58]
Lung cancer
Knockdown in NCI-H441 cells
Knockdown decreased cell proliferation and survival
[62]
Pancreatic cancer
Knockdown in CFPAC-1 cells
Downregulation decreased cell proliferation and survival in vitro and reduced tumour growth in vivo
[62]
Retinoblastoma
Knockdown in Y79 cells and overexpression in Meri-RB1 cells
Knockdown led to cell cycle arrest at the G1 phase, decreased cell proliferation and increased apoptosis. Overexpression increased cell proliferation.
[57]
HCC: hepatocellular carcinoma
Alpha-enolase is a surface plasminogen-binding receptor
In addition to a role in cell proliferation and survival, α-enolase located on the plasma membrane acts as a plasminogen-binding receptor[55][Figure 3]. Plasminogen is a zymogen, which is converted to plasmin in the presence of the activators tissue plasminogen activator or urokinase-type plasminogen activator (uPA)[65]. This cell surface interaction concentrates protease activity in the tissue surrounding the cell, protecting plasmin from inactivation by circulating α2-antiplasmin[66]. Plasmin activates collagenases and degrades fibrin and other matrix proteins, resulting in cell migration and invasion into tissue, ultimately underpinning cancer metastasis and relapse.
Alpha-enolase acts as a surface plasminogen-binding receptor to mediate cancer cell invasion and metastasis formation. PLG binds to its receptors and is subsequently converted to PLIN by plasminogen activators (e.g., uPA). Cell surface-associated plasmin facilitates degradation of the ECM, allowing tumour cells to invade and metastasise into other tissues. PLG: plasminogen; PLIN: plasmin; ECM: extracellular matrix; uPA: urokinase-type plasminogen activator
Role in invasion and migration
Overexpression of α-enolase has been shown to increase the migration and invasion of hepatocellular carcinoma, colorectal and gastric cancer cells in vitro[11,58,60,61,67] and to enhance colorectal cancer metastasis in vivo[11], demonstrating that it is an important driver of metastasis in multiple cancer types [Table 3]. Conversely, knockdown or pharmacological inhibition of α-enolase decreased the migration and invasion of glioma, colorectal, pancreatic and endometrial carcinoma in vitro[6,12,63,68,69], and decreased tumourigenesis and metastasis of endometrial carcinoma in vivo[12]. Furthermore, binding of recombinant α-enolase to the surface of prostate cancer cells was shown to promote cell migration via its plasminogen receptor activity[70]. By contrast, anti-α-enolase monoclonal antibodies inhibited plasminogen-dependent invasion of human pancreatic cancer cells in vitro and metastasis formation in vivo[71] and also lung cancer cell invasion in vitro and growth in vivo[72][Table 3].
Alpha-enolase is a potential regulator of metastasis
Cancer
Experimental model
Effect of modulation of ENO1 expression
Ref.
Colorectal cancer
Overexpression and knockdown in HCT116 cells
Overexpression increased migration and invasion both in vitro and in vivo; decreased expression decreased migration and invasion both in vitro and in vivo
[11]
Treatment of HCT116 cells with CS5931 (peptide inhibitor)
Treatment with CS5931 decreased cell migration and invasion
[69]
Endometrial carcinoma
Knockdown in HEC-1B and Ishikawa
Decreased expression reduced migration and invasion in vitro and metastasis in vivo
[12]
Gastric cancer
Knockdown in AGS cells and overexpression in SGC7901 cells
Knockdown decreased migration, and overexpression increased migration
[60]
Overexpression in AGS cells
Overexpression increased migration
[61]
Glioma
Knockdown in U251-MG-WBP2 cells
Knockdown decreased migration
[63]
Knockdown in U-87MG cells
Knockdown suppressed migration and invasion
[6]
HCC
Knockdown in HCC cells
Knockdown inhibited migration
[58]
Overexpression in HepG-2 cells
Increased migration and invasion
[67]
Lung cancer
Anti-human ENO1 antibody and knockdown in A549 cells
Downregulation and adoptive transfer of anti-human ENO1 antibody decreased invasion in vitro and in vivo
[72]
Pancreatic cancer
Knockdown in CFPAC-1 cells
Knockdown decreased migration and invasion, and reduced adhesion to fibronection and collagen and increased adhesion to vitronectin
[68]
Anti-human ENO1 antibody
Decreased invasion in vitro and metastasis in vivo
[71]
HCC: hepatocellular carcinoma
Alpha-enolase is a tumour-associated antigen
Externalisation of α-enolase by cancer cells exposes it to the immune system as a tumour-associated antigen that has been found to induce autoantibody production in cancer patients, including those with acute and chronic leukaemias, melanoma, and lung, breast, gastric and pancreatic cancers[22,45,73-79]. In pancreatic cancer, T cells activated by α-enolase-pulsed dendritic cells lysed pancreatic cancer cells, but not normal human keratinocytes in vitro and inhibited CF-PAC-1 tumour growth in vivo[22]. In oral squamous cell carcinoma, an HLA-DR8-restricted human α-enolase peptide was recognised by CD4+ T cells and produced a cytotoxic response against OSC-20 cells[80]. Additionally, vaccination with ENO1 in KrasG12D/Cre and KrasG12D/Trp53R172H mice prior to development of pancreatic carcinoma delayed tumour growth and increased survival[81]. Taken together, these studies suggest that immune responses directed against α-enolase may be immunostimulatory and ultimately beneficial to patients.
Alpha-enolase is a prognostic factor for multiple cancer types
In addition to being overexpressed in many cancers, α-enolase has been identified as a putative prognostic biomarker in a range of tumour types [Table 4]. Whilst ENO1 expression was not associated with tumour stage in colorectal cancers, it was significantly correlated with tumour size and presence of distant metastases[11]. Alpha-enolase expression was positively correlated with lymph node status in endometrial and gastric cancer patients[12,13,60], and increased α-enolase expression in endometrial, gastric, lung, lymphoma and hepatocellular cancer patients was associated with worse overall survival[8,12,13,16,73,82]. Furthermore, increased α-enolase expression was correlated with worse distant metastasis-free survival in breast cancer patients[9], worse disease-free survival in hepatocellular carcinoma and chordoma[16,83] and worse progression-free survival in lung cancer patients[73]. By contrast, downregulation of α-enolase is a predictor of poor prognosis in clear cell renal cell carcinoma (ccRCC)[84], demonstrating that α-enolase may control different cellular functions in ccRCC when compared to other cancers.
α-Enolase is a prognostic biomarker for a range of cancer types
Cancer
Sample type
Patient outcome
Ref.
Breast cancer
Kaplan-Meier Plotter database (n = 5143 breast cancer patients)
Increased mRNA expression correlated with worse DMFS
[9]
Chordoma
Cervical or sacral spine chordomas (n = 39)
Increased protein expression was associated with worse disease-free survival
[83]
CLL
Sera from CLL patients (n = 86)
Presence of anti-α-enolase antibodies was predictive of a shorter time to first treatment
[90]
Colorectal cancer
Colorectal tumour tissues (n = 41)
Protein expression correlated with tumour size and distant metastasis
[11]
Endometrial cancer
Endometrial cancer tissue (n = 100)
Protein expression correlated with lymph node status and depth of myometrial invasion; patients with high expression had worse OS
[12]
Gastric cancer
Gastric cancer tissue (n = 76)
Protein expression correlated with lymph node metastasis and TNM stage
[60]
TCGA dataset (n = 410 gastric cancer patients); Gastric cancer tissue (n = 94)
Protein expression correlated with high TNM stage and metastasis; Increased mRNA was associated with poor OS
[13]
HCC
TCGA dataset (n = 374 HCC tissues); meta-analysis of 12 cohorts in GEO database
Increased mRNA was associated with poor OS and disease-free survival; Protein expression correlated with high TNM stage and was negatively correlated with OS
[16]
Sera from HCC patients (n = 61)
Anti-α-enolase antibodies were lower in patients without microvascular invasion compared to those with microvascular invasion
Increased mRNA and protein was associated with poor OS; Increased expression was associated with bone metastasis incidence
[82]
Malignant pleural effusion samples (n = 54)
High protein was associated with poor OS and PFS
[73]
Plasma from non-small lung carcinoma patients (n = 85)
Patients with a higher increase in anti-α-enolase had a lower hazard ratio and better PFS
[85]
Sera from patients with lung cancer (n = 72), benign lung diseases (n = 69), and healthy individuals (n = 70)
Autoantibodies were higher in lung cancer sera compared with sera from normal and benign lung disease patients; Autoantibodies were higher in stage I/II than in stage III/IV
[89]
Lymphoma
Peripheral T-cell lymphoma not otherwise classified tissue (n = 87)
Increased protein correlated with worse OS
[8]
Pancreatic cancer
Sera from pancreatic ductal adenocarcinoma patients (n = 120)
Presence of auto-antibodies correlated with a better clinical outcome
[86]
Sera and PBMCs from pancreatic ductal adenocarcinoma patients (n = 15)
Patients with > 20% peripheral α-enolase-specific T cells or anti-α-enolase antibodies showed a better OS
Autoantibodies generated against α-enolase in its capacity as a tumour-associated antigen represent an additional type of prognostic biomarker that may be assayed in serum. The presence of autoantibodies against α-enolase correlated with longer disease-free survival and overall survival in pancreatic and lung cancer patients[45,85-87][Table 4]. Furthermore, compared with healthy individuals, α-enolase antibodies are decreased in stage IV lung and breast cancers[88], and are lower in stage III/IV than in stage I/II lung cancer patients[89]. By contrast, the presence of anti-α-enolase antibodies in sera from chronic lymphocytic leukaemia (CLL) patients is predictive of a shorter time to first treatment[90], indicating that the presence of α-enolase antibodies are indicative of a disrupted immune system in CLL. Taken together, these studies suggest that autoantibodies against α-enolase are a good prognostic factor in pancreatic, lung and breast cancers, and provide further evidence that targeting α-enolase may be beneficial in solid tumours.
Enolase inhibitors are potential anticancer agents
Due to its important cancer-related roles, enolase is one of several glycolytic enzymes being examined as a potential anticancer therapeutic target. Polyamine sulphonamide analogues have proven particularly effective at inhibiting α-enolase activity. Two such compounds have been further developed and shown to be cytotoxic to KG-1 (AML) cells and to the AML leukaemic stem cell fraction, with minimal effects on normal healthy stem cells[92]. This report highlights that α-enolase is an actionable therapeutic target that may be useful in the treatment of cancer, particularly AML.
Conclusion
Alpha-enolase plays a supportive role in cancer progression and has been implicated in three of the hallmarks of cancer: cellular energetics and metabolism; cell proliferation; and invasion and migration. In cancer cells, α-enolase is overexpressed and localised on the surface, where it acts as a key promotor of metastasis, driving invasion through plasminogen activation and extracellular matrix degradation. In several cancer types, patients develop an immune response against α-enolase, and anti-α-enolase antibodies can be detected in their sera. Increased expression of α-enolase mRNA, proteins or autoantibodies are associated with decreased metastasis-free survival in several cancer types, including non-small cell lung, pancreatic, breast and colorectal cancers. Future examination of the expression and function of α-enolase in cancers may ultimately result in α-enolase becoming a therapeutic target and prognostic biomarker for a range of cancer types.
DeclarationsAuthors’ contributions
Contributed to the drafting and editing of this manuscript: Schofield L, Lincz LF, Skelding KA
Availability of data and materials
Not applicable.
Financial support and sponsorship
This work was funded by grants from the Calvary Mater Newcastle and Hunter Medical Research Institute.
Conflicts of interest
All authors declared that there are no conflicts of interest.
LibertiMVLocasaleJWThe warburg effect: how does it benefit cancer cells?201641211810.1016/j.tibs.2015.12.00126778478PMC4783224HanahanDWeinbergRAHallmarks of cancer: the next generation.20111446467410.1016/j.cell.2011.02.01321376230KimJWDangCVMultifaceted roles of glycolytic enzymes.2005301425010.1016/j.tibs.2005.01.00515752986HandschuhLKazmierczakMMilewskiMCGoralskiMLuczakMGene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.2018526567810.3892/ijo.2017.423329286103PMC5807040BecknerMEFellows-MayleWZhangZAgostinoNRKantJAIdentification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas.201012622829510.1002/ijc.2491819795461PMC2847004SongYLuoQLongHHuZQueTAlpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma.2014136510.1186/1476-4598-13-6524650096PMC3994408CecconiDCarbonareLDMoriACheriSDeianaMAn integrated approach identifies new oncotargets in melanoma.201891148950210.18632/oncotarget.2372729545914PMC5837771LudvigsenMBjerregardPedersen MLystlundLauridsen KSvenstrupPoulsen THamilton-DutoitSJProteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified.2018225334210.1182/bloodadvances.201801989330291111PMC6177647CancemiPButtacavoliMRozEFeoSExpression of alpha-enolase (ENO1), myc promoter-binding protein-1 (MBP-1) and matrix metalloproteinases (MMP-2 and MMP-9) reflect the nature and aggressiveness of breast tumors.20192010.3390/ijms2016395231416219PMC6720302TuSHChangCCChenCSTamKWWangYJIncreased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells.20101215395310.1007/s10549-009-0492-019655245ZhanPZhaoSYanHYinCXiaoYalpha-enolase promotes tumorigenesis and metastasis via regulating AMPK/mTOR pathway in colorectal cancer.20175614273710.1002/mc.2260327996156ZhaoMFangWWangYGuoSShuLEnolase-1 is a therapeutic target in endometrial carcinoma.20156156102710.18632/oncotarget.363925951350PMC4558174QiaoHWangYZhuBJiangLYuanWEnolase1 overexpression regulates the growth of gastric cancer cells and predicts poor survival.2019120187142310.1002/jcb.2917931218757ZhouXYaoKZhangLZhangYHanYIdentification of differentiation-related proteins in gastric adenocarcinoma tissues by proteomics.20161569770610.1177/153303461559579227624754TsaiSTChienIHShenWHKuoYZJinYTENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction.20104617122310.1016/j.ejca.2010.03.01820435467ZhuWLiHYuYChenJChenXEnolase-1 serves as a biomarker of diagnosis and prognosis in hepatocellular carcinoma patients.20181057354510.2147/CMAR.S18218330532594PMC6245378FuQFLiuYFanYHuaSNQuHYAlpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway.201582210.1186/s13045-015-0117-525887760PMC4359783RaczABrassNHoferMSybrechtGWRembergerKGene amplification at chromosome 1pter-p33 including the genes PAX7 and ENO1 in squamous cell lung carcinoma.200017677310.3892/ijo.17.1.6710853020CruzINColeyHMKramerHBMadhuriTKSafuwanNAProteomics analysis of ovarian cancer cell lines and tissues reveals drug resistance-associated proteins.201714355110.21873/cgp.2001728031236PMC5267499YinHWangLLiuHLENO1 overexpression in pancreatic cancer patients and its clinical and diagnostic significance.20182018384219810.1155/2018/384219829483925PMC5816842SunLGuoCCaoJBurnettJYangZOver-expression of alpha-enolase as a prognostic biomarker in patients with pancreatic cancer.2017146556110.7150/ijms.1873628824297PMC5562116CappelloPTomainoBChiarleRCerutiPNovarinoAAn integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen.20091256394810.1002/ijc.2435519425054MarangosPJParmaAMGoodwinFKFunctional properties of neuronal and glial isoenzymes of brain enolase.1978317273210.1111/j.1471-4159.1978.tb07847.x681951KangHJJungSKKimSJChungSJStructure of human alpha-enolase (hENO1), a multifunctional glycolytic enzyme.200864651710.1107/S090744490800856118560153BrewerJMYeast enolase: mechanism of activation by metal ions.1981112095410.3109/104092381091087027030619PetrakJIvanekRTomanOCmejlaRCmejlovaJDeja vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins.200881744910.1002/pmic.20070091918442176CastegnaAAksenovMThongboonkerdVKleinJBPierceWMProteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71.20028215243210.1046/j.1471-4159.2002.01103.x12354300OwenJBDi DomenicoFSultanaRPerluigiMCiniCProteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer’s disease and mild cognitive impairment: implications for progression of AD.200984718210.1021/pr800667a19072283PMC2658606ButterfieldDALangeMLMultifunctional roles of enolase in Alzheimer’s disease brain: beyond altered glucose metabolism.20091119153310.1111/j.1471-4159.2009.06397.x19780894PMC4454338KinlochATatzerVWaitRPestonDLundbergKIdentification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis.20057R1421910.1186/ar184516277695PMC1297593MontesADieguez-GonzalezRPerez-PampinECalazaMMera-VarelaAParticular association of clinical and genetic features with autoimmunity to citrullinated alpha-enolase in rheumatoid arthritis.2011636546110.1002/art.3018621360494MehraSWalkerJPattersonKFritzlerMJAutoantibodies in systemic sclerosis.2013123405410.1016/j.autrev.2012.05.01122743034TerrierBTambyMCCamoinLGuilpainPBerezneAAntifibroblast antibodies from systemic sclerosis patients bind to {alpha}-enolase and are associated with interstitial lung disease.2010694283310.1136/ard.2008.10429919293162BergmannSSchoenenHHammerschmidtSThe interaction between bacterial enolase and plasminogen promotes adherence of Streptococcus pneumoniae to epithelial and endothelial cells.20133034526210.1016/j.ijmm.2013.06.00223906818FunkJSchaarschmidtBSlesionaSHallstromTHornUThe glycolytic enzyme enolase represents a plasminogen-binding protein on the surface of a wide variety of medically important fungal species.2016306596810.1016/j.ijmm.2015.11.00526679571LiMLiJWangJLiYYangPSerum level of anti-alpha-enolase antibody in untreated systemic lupus erythematosus patients correlates with 24-hour urine protein and D-dimer.2018271394210.1177/096120331772175228728510PengBHuangXNakayasuESPetersenJRQiuSUsing immunoproteomics to identify alpha-enolase as an autoantigen in liver fibrosis.20131217899610.1021/pr301134223458688PMC3743961ZhangBWangZDengBWuXLiuJIdentification of Enolase 1 and Thrombospondin-1 as serum biomarkers in HBV hepatic fibrosis by proteomics.2013113010.1186/1477-5956-11-3023845056PMC3734151FeoSArcuriDPiddiniEPassantinoRGiallongoAENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1).2000473475210.1016/s0014-5793(00)01494-010802057BaeSMMinHJDingGHKwakSYChoYLProtein expression profile using two-dimensional gel analysis in squamous cervical cancer patients.2006389910710.4143/crt.2006.38.2.9919771267PMC2741666KatayamaMNakanoHIshiuchiAWuWOshimaRProtein pattern difference in the colon cancer cell lines examined by two-dimensional differential in-gel electrophoresis and mass spectrometry.20063610859310.1007/s00595-006-3301-y17123137ChangYSWuWWalshGHongWKMaoLEnolase-alpha is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior.200393641414506152DuijveszDBurnum-JohnsonKEGritsenkoMAHooglandAMVredenbregt-van den BergMSProteomic profiling of exosomes leads to the identification of novel biomarkers for prostate cancer.20138e8258910.1371/journal.pone.008258924391718PMC3876995SewerynEPietkiewiczJBednarz-MisaISCeremugaISaczkoJLocalization of enolase in the subfractions of a breast cancer cell line.200964754810.1515/znc-2009-9-102319957447HePNakaTSeradaSFujimotoMTanakaTProteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer.20079812344010.1111/j.1349-7006.2007.00509.x17506794MearsRCravenRAHanrahanSTottyNUptonCProteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry.2004440193110.1002/pmic.20040087615478216GreeningDWJiHChenMRobinsonBWDickIMSecreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.201663264310.1038/srep3264327605433PMC5015102PanDChenJFengCWuWWangYPreferential localization of MUC1 glycoprotein in exosomes secreted by non-small cell lung carcinoma cells.20192010.3390/ijms2002032330646616PMC6358839ValczGGalambOKrenacsTSpisakSKalmarAExosomes in colorectal carcinoma formation: ALIX under the magnifying glass.2016299283810.1038/modpathol.2016.7227150162DidiasovaMSchaeferLWygreckaMWhen place matters: shuttling of enolase-1 across cellular compartments.201976110.3389/fcell.2019.0006131106201PMC6498095EntelisNBrandinaIKamenskiPKrasheninnikovIAMartinRPA glycolytic enzyme, enolase, is recruited as a cofactor of tRNA targeting toward mitochondria in Saccharomyces cerevisiae.20062016092010.1101/gad.38570616738406PMC1482481BrandinaIGrahamJLemaitre-GuillierCEntelisNKrasheninnikovIEnolase takes part in a macromolecular complex associated to mitochondria in yeast.2006175712172810.1016/j.bbabio.2006.07.00116962558GaoSLiHCaiYYeJTLiuZPMitochondrial binding of alpha-enolase stabilizes mitochondrial membrane: its role in doxorubicin-induced cardiomyocyte apoptosis.2014542465510.1016/j.abb.2013.12.00824361255AaronsonRMGravenKKTucciMMcDonaldRJFarberHWNon-neuronal enolase is an endothelial hypoxic stress protein.199527027752710.1074/jbc.270.46.277527499243PlowEFDasREnolase-1 as a plasminogen receptor.20091135371210.1182/blood-2009-03-208546LuntSYVander HeidenMGAerobic glycolysis: meeting the metabolic requirements of cell proliferation.2011274416410.1146/annurev-cellbio-092910-15423721985671LiuYLiHLiuYZhuZMiR-22-3p targeting alpha-enolase 1 regulates the proliferation of retinoblastoma cells.20181058051210.1016/j.biopha.2018.06.03829913409ZhuXYuHLiBQuanJZengZTargetting an LncRNA P5848-ENO1 axis inhibits tumor growth in hepatocellular carcinoma.20193910.1042/BSR2018089630541900PMC6859111JiMWangZChenJGuLChenMUp-regulated ENO1 promotes the bladder cancer cell growth and proliferation via regulating beta-catenin.20193910.1042/BSR2019050331431517PMC6734116SunLLuTTianKZhouDYuanJAlpha-enolase promotes gastric cancer cell proliferation and metastasis via regulating AKT signaling pathway.201984581510.1016/j.ejphar.2018.12.03530582908LiuYQHuangZGLiGNDuJLOuYPEffects of alpha-enolase (ENO1) over-expression on malignant biological behaviors of AGS cells.20158231925784992PMC4358447CapelloMFerri-BorgognoSRigantiCChattaragadaMSPrincipeMTargeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest.20167559861210.18632/oncotarget.679826734996PMC4868708ChenSZhangYWangHZengYYLiZWW domain-binding protein 2 acts as an oncogene by modulating the activity of the glycolytic enzyme ENO1 in glioma.2018934710.1038/s41419-018-0376-529497031PMC5832848QiaoHWangYFYuanWZZhuBDJiangLSilencing of ENO1 by shRNA inhibits the proliferation of gastric cancer cells.201817153303381878441110.1177/153303381878441129986635PMC6048655SyrovetsTLunovOSimmetTPlasmin as a proinflammatory cell activator.2012925091910.1189/jlb.021205622561604RedlitzAFowlerBJPlowEFMilesLAThe role of an enolase-related molecule in plasminogen binding to cells.19952274071510.1111/j.1432-1033.1995.tb20403.x7851415ChenXXuHWuNLiuXQiaoGInteraction between granulin A and enolase 1 attenuates the migration and invasion of human hepatoma cells.20178303051610.18632/oncotarget.1632828415822PMC5444744PrincipeMBorgoniSCascioneMChattaragadaMSFerri-BorgognoSAlpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis.2017101610.1186/s13045-016-0385-828086938PMC5237223SuSXuHChenXQiaoGFarooqiAACS5931, A novel marine polypeptide, inhibits migration and invasion of cancer cells via interacting with enolase 1.201813360710.2174/157489281366618062817024029956637YuLShiJChengSZhuYZhaoXEstrogen promotes prostate cancer cell migration via paracrine release of ENO1 from stromal cells.20122615213010.1210/me.2012-100622734040PMC5416971PrincipeMCerutiPShihNYChattaragadaMSRollaSTargeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells.201561109811310.18632/oncotarget.357225860938PMC4484442HsiaoKCShihNYFangHLHuangTSKuoCCSurface alpha-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target.20138e6935410.1371/journal.pone.006935423894455PMC3716638ChangGCLiuKJHsiehCLHuTSCharoenfuprasertSIdentification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes.20061257465410.1158/1078-0432.CCR-06-032417020980DaiLQuYLiJWangXWangKSerological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.20178366647310.18632/oncotarget.1706728456790PMC5482686QinJWangSShiJMaYWangKUsing recursive partitioning approach to select tumor-associated antigens in immunodiagnosis of gastric adenocarcinoma.201911018294110.1111/cas.1401330950146PMC6550128SuzukiAIizukaAKomiyamaMTakikawaMKumeAIdentification of melanoma antigens using a Serological Proteome Approach (SERPA).20107172320181627CuiJWLiWHWangJLiALLiHYProteomics-based identification of human acute leukemia antigens that induce humoral immune response.2005417182410.1074/mcp.M400165-MCP20016081408ZouLWuYPeiLZhongDGenMIdentification of leukemia-associated antigens in chronic myeloid leukemia by proteomic analysis.20052913879110.1016/j.leukres.2005.04.02115936817ForgberMTrefzerUSterryWWaldenPProteome serological determination of tumor-associated antigens in melanoma.20094e519910.1371/journal.pone.000519919381273PMC2667248KondoHSaharaHMiyazakiANabetaYHirohashiYNatural antigenic peptides from squamous cell carcinoma recognized by autologous HLA-DR8-restricted CD4+ T cells.2002939172410.1111/j.1349-7006.2002.tb01338.x12716470PMC5927106CappelloPRollaSChiarleRPrincipeMCavalloFVaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer.2013144109810610.1053/j.gastro.2013.01.02023333712YangMSunYSunJWangZZhouYDifferentially expressed and survival-related proteins of lung adenocarcinoma with bone metastasis.2018710819210.1002/cam4.136329522283PMC5911611ZhouHChenCBLanJLiuCLiuXGDifferential proteomic profiling of chordomas and analysis of prognostic factors.2010102720710.1002/jso.2167420721957White-Al HabeebNMDi MeoAScorilasARotondoFMasuiOAlpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma.2015325314110.1007/s10585-015-9725-226037892HsiaoKCShihNYChuPYHungYMLiaoJYAnti-alpha-enolase is a prognostic marker in postoperative lung cancer patients.20156350738610.18632/oncotarget.531626551021PMC4741510TomainoBCappelloPCapelloMFredoliniCSperdutiICirculating autoantibodies to phosphorylated alpha-enolase are a hallmark of pancreatic cancer.2011101051210.1021/pr100213b20455595NiccolaiECappelloPTaddeiARicciFD’EliosMMPeripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma.20164939340110.3892/ijo.2016.352427210467ShihNYLaiHLChangGCLinHCWuYCAnti-alpha-enolase autoantibodies are down-regulated in advanced cancer patients.201040663910.1093/jjco/hyq02820395242ZhangLWangHDongXDiagnostic value of alpha-enolase expression and serum alpha-enolase autoantibody levels in lung cancer.201844182310.1590/S1806-3756201600000024129538538PMC6130332GriggioVMandiliGVitaleCCapelloMMacorPHumoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia.2017832748810.18632/oncotarget.1371227906678PMC5356881YuYQWangLJinYZhouJLGengYHIdentification of serologic biomarkers for predicting microvascular invasion in hepatocellular carcinoma.20167163627110.18632/oncotarget.764926918350PMC4941320FortunatoSBononiGGranchiCMinutoloFAn update on patents covering agents that interfere with the cancer glycolytic cascade.20181322516510.1002/cmdc.20180044730226288